%0 Generic %A P.P., Reese %A A.R., Cappola %A J., Shults %A R.R., Townsend %A C.A., Gadegbeku %A C., Anderson %A J.F., Baker %A D., Carlow %A M.J., Sulik %A J.C., Lo %D 2013 %T Supplementary Material for: Physical Performance and Frailty in Chronic Kidney Disease %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Physical_Performance_and_Frailty_in_Chronic_Kidney_Disease/5125696 %R 10.6084/m9.figshare.5125696.v1 %2 https://karger.figshare.com/ndownloader/files/8712802 %K Physical performance %K Frailty %K Chronic kidney disease %X Background: Poor physical performance and frailty are associated with elevated risks of death and disability. Chronic kidney disease (CKD) is also strongly associated with these outcomes. The risks of poor physical performance and frailty among CKD patients, however, are not well established. Methods: We measured the Short Physical Performance Battery (SPPB; a summary test of gait speed, chair raises and balance; range 0-12) and the five elements of frailty among 1,111 Chronic Renal Insufficiency Cohort participants. Adjusting for demographics and multiple comorbidities, we fit a linear regression model for the outcome of SPPB score and an ordinal logistic regression model for frailty status. Results: Median (interquartile range, IQR) age was 65 (57-71) years, median estimated glomerular filtration rate (eGFR) for non-dialysis patients was 49 (36-62) ml/min/1.73 m2, and median SPPB score was 9 (7-10). Seven percent of participants were frail and 43% were pre-frail. Compared with the SPPB score for eGFR >60 ml/min/1.73 m2, the SPPB was 0.51 points lower for eGFR 30-59; 0.61 points lower for eGFR 15-29, and 1.75 points lower for eGFR <15 (p < 0.01 for all comparisons). eGFR 30-59 (odds ratio, OR 1.45; p = 0.024), eGFR 15-29 (OR 2.02; p = 0.002) and eGFR <15 (OR 4.83; p < 0.001) were associated with worse frailty status compared with eGFR >60 ml/min/1.73 m2. Conclusions: CKD severity was associated with poor physical performance and frailty in a graded fashion. Future trials should determine if outcomes for CKD patients with frailty and poor physical performance are improved by targeted interventions. %I Karger Publishers